Yes, Continue Progesterone for 12-14 Days Monthly
Even though your patient has no menses (amenorrhea), she should still receive cyclic oral micronized progesterone for 12-14 days every 28 days when taking continuous transdermal estradiol. The absence of menstrual bleeding does not change the requirement for endometrial protection.
Why Progesterone Duration Remains 12-14 Days
The 12-14 day duration is based on endometrial protection requirements, not menstrual status. When a woman with a uterus receives continuous estrogen therapy (transdermal or otherwise), the endometrium requires adequate progestogen exposure to prevent hyperplasia and reduce endometrial cancer risk 1.
Key Evidence Supporting This Regimen:
Multiple 2021 guidelines specifically recommend transdermal 17β-estradiol administered continuously with oral/vaginal progestin for 12-14 days every 28 days in amenorrheic patients with premature ovarian insufficiency 1
The FDA-approved dosing for progesterone capsules states: "200 mg orally for 12 days sequentially per 28-day cycle" for prevention of endometrial hyperplasia in postmenopausal women receiving estrogen 2
A 2016 systematic review confirmed that oral micronized progesterone provides endometrial protection when applied sequentially for 12-14 days/month at 200 mg/day 3
The 2016 ESHRE guideline on premature ovarian insufficiency recommends oral micronized progesterone 100-200 mg/day or dydrogesterone 5-10 mg/day during 12-14 days of the month 4
Practical Dosing Protocol
For your amenorrheic patient on continuous transdermal estradiol:
- Estradiol: Continue transdermal patches (typically 50-100 μg daily) continuously without interruption
- Progesterone: Add oral micronized progesterone 200 mg daily at bedtime for 12-14 consecutive days every 28 days 1
- Alternative: Medroxyprogesterone acetate 10 mg daily for 12-14 days per month
- Alternative: Dydrogesterone 10 mg daily for 12-14 days per month
Important Clinical Considerations:
Micronized progesterone is the preferred progestogen due to its superior safety profile regarding cardiovascular disease, venous thromboembolism risk, and breast cancer risk compared to synthetic progestogens 1
Timing matters: Progesterone should be taken at bedtime as it can cause drowsiness, dizziness, and rarely blurred vision or difficulty speaking 2
Withdrawal bleeding may or may not occur: Some amenorrheic patients will experience withdrawal bleeding after the progesterone phase, while others will not. The absence of bleeding does NOT indicate inadequate endometrial protection, as long as the proper duration (12-14 days) is maintained 1
Common Pitfall to Avoid
Do not shorten the progesterone duration just because the patient is amenorrheic. The 12-14 day duration is the minimum required for adequate endometrial protection based on histologic studies. Shorter durations (e.g., 10 days) may be insufficient for long-term endometrial safety, particularly with continuous estrogen exposure 3.
Exception: In adolescents with Turner syndrome or other causes of delayed puberty, cyclic progestogens should only begin after at least 2 years of estrogen therapy or when breakthrough bleeding occurs 4. However, this does not apply to your post-pubertal amenorrheic patient.